Withania somnifera (L.) Dunal (Ashwagandha) for the possible therapeutics and clinical management of SARS-CoV-2 infection: Plant-based drug discovery and targeted therapy
Singh M, Jayant K, Singh D, Bhutani S, Poddar NK, Chaudhary AA, Khan SU, Adnan M, Siddiqui AJ, Hassan MI, Khan FI, Lai D, Khan S
Frontiers in cellular and infection microbiology · 19 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (clasificado por nuestro filtro de IA)
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- China Postdoctoral Science Foundation
- Gobierno
- Sichuan Province Science and Technology Support Program
- Subvenciones
- China Postdoctoral Science Foundation (2020M 673187); Sichuan Province Science and Technology Support Program (2021YFH0093)
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2022-08-15 · Front Cell Infect Microbiol · vol. 12 · pág. 933824
- Editorial
- Frontiers Media
- Citado
- 39 citas · más que el 98% de estudios similares · 9.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 150 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Phytochemicals and Medicinal Plants · SARS-CoV-2 and COVID-19 Research · Diverse Scientific Research Studies
- Palabras clave
- Withania somnifera, Medicine, Traditional medicine, Pharmacology, Coronavirus, Medicinal plants, Biology, Immunology, Coronavirus disease 2019 (COVID-19), Disease, Infectious disease (medical specialty), Internal medicine, Pathology, Alternative medicine
- MeSH
- humans, withania, plant extracts, antiviral agents, aged, drug discovery, sars-cov-2, covid-19 drug treatment
15 autores
- Manali Singh🇮🇳Invertis University; Govind Ballabh Pant University of Agriculture and Technology
- Kuldeep Jayant🇮🇳Indian Institute of Technology Kharagpur
- Dipti Singh🇮🇳Govind Ballabh Pant University of Agriculture and Technology
- Shivani Bhutani🇮🇳Invertis University
- Nitesh Kumar Poddar · autor de correspondenciaManipal University Jaipur
- Anis Ahmad Chaudhary🇸🇦Imam Mohammad ibn Saud Islamic University
- Salah-Ud-Din Khan🇸🇦 · autor de correspondenciaImam Mohammad ibn Saud Islamic University; King Saud University
- Salah-Ud-Din Khan🇸🇦Imam Mohammad ibn Saud Islamic University; King Saud University; University of Ha'il
- Mohd Adnan🇸🇦University of Ha'il
- Arif Jamal Siddiqui🇸🇦🇮🇳University of Ha'il; Jamia Millia Islamia
- Md. Imtaiyaz Hassan🇨🇳🇮🇳University of Electronic Science and Technology of China; Jamia Millia Islamia; Xi’an Jiaotong-Liverpool University
- Faez Iqbal Khan🇨🇳University of Electronic Science and Technology of China; Xi’an Jiaotong-Liverpool University
- Dakun Lai🇨🇳🇸🇦 · autor de correspondenciaUniversity of Electronic Science and Technology of China; King Saud University
- Shahanavaj Khan🇸🇦Imam Mohammad ibn Saud Islamic University; King Saud University
- Shahanavaj Khan🇸🇦 · autor de correspondenciaImam Mohammad ibn Saud Islamic University; King Saud University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Coronavirus disease 2019 (COVID-19) pandemic has killed huge populations throughout the world and acts as a high-risk factor for elderly and young immune-suppressed patients. There is a critical need to build up secure, reliable, and efficient drugs against to the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Bioactive compounds of Ashwagandha [Withania somnifera (L.) Dunal] may implicate as herbal medicine for the management and treatment of patients infected by SARS-CoV-2 infection. The aim of the current work is to update the knowledge of SARS-CoV-2 infection and information about the implication of various compounds of medicinal plant Withania somnifera with minimum side effects on the patients' organs. The herbal medicine Withania somnifera has an excellent antiviral activity that could be implicated in the management and treatment of flu and flu-like diseases connected with SARS-CoV-2. The analysis was performed by systematically re-evaluating the published articles related to the infection of SARS-CoV-2 and the herbal medicine Withania somnifera. In the current review, we have provided the important information and data of various bioactive compounds of Withania somnifera such as Withanoside V, Withanone, Somniferine, and some other compounds, which can possibly help in the management and treatment of SARS-CoV-2 infection. Withania somnifera has proved its potential for maintaining immune homeostasis of the body, inflammation regulation, pro-inflammatory cytokines suppression, protection of multiple organs, anti-viral, anti-stress, and anti-hypertensive properties. Withanoside V has the potential to inhibit the main proteases (Mpro) of SARS-CoV-2. At present, synthetic adjuvant vaccines are used against COVID-19. Available information showed the antiviral activity in Withanoside V of Withania somnifera, which may explore as herbal medicine against to SARS-CoV-2 infection after standardization of parameters of drug development and formulation in near future.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.